Mittle Doyle, M.D, FACR

Mittle Doyle, M.D, FACR

Chief Medical OfficeratAvalo Therapeutics· In proxies 2023–2025

Pay in FY2025-41% from the year before · Avalo Therapeutics stock +144.4% the same year

Mittle Doyle, M.D, FACR was paid $1.8M in FY2025 (Dec), down 41%. Avalo Therapeutics stock rose 144.4% that year.

Pay$100 in the stock at the end of FY22 → $2
Pay is from the Summary Compensation Table of each Avalo Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Avalo TherapeuticsPublic company · 3 yr
    • Chief Medical Officer2023 – Present · 3 yrStock in role -99%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?